Lantheus Holdings Management
Management criteria checks 2/4
Lantheus Holdings' CEO is Brian Markison, appointed in Mar 2024, has a tenure of 1.08 years. total yearly compensation is $13.44M, comprised of 6.4% salary and 93.6% bonuses, including company stock and options. directly owns 0.076% of the company’s shares, worth $5.34M. The average tenure of the management team and the board of directors is 2.1 years and 7.2 years respectively.
Key information
Brian Markison
Chief executive officer
US$13.4m
Total compensation
| CEO salary percentage | 6.4% |
| CEO tenure | 1.1yrs |
| CEO ownership | 0.08% |
| Management average tenure | 2.1yrs |
| Board average tenure | 7.2yrs |
Recent management updates
Recent updates
Lantheus Holdings: Pylarify Makes Bull Case Despite Looming Patent Expiry
Mar 07Lacklustre Performance Is Driving Lantheus Holdings, Inc.'s (NASDAQ:LNTH) Low P/E
Feb 13
Lantheus Holdings (NASDAQ:LNTH) Seems To Use Debt Rather Sparingly
Jan 26Lantheus Holdings: Powerhouse Potential In 2025
Jan 02If EPS Growth Is Important To You, Lantheus Holdings (NASDAQ:LNTH) Presents An Opportunity
Dec 21Lantheus Holdings' (NASDAQ:LNTH) Earnings Are Weaker Than They Seem
Nov 13Lantheus Holdings: Q3 Results Were Good But Market Overreacted
Nov 08Investors Still Waiting For A Pull Back In Lantheus Holdings, Inc. (NASDAQ:LNTH)
Nov 03Lantheus: PYLARIFY's Enhanced Prospects Are Welcome, But Don't Get Too Greedy Now
Oct 21Lantheus Holdings (NASDAQ:LNTH) Is Achieving High Returns On Its Capital
Oct 16We Think Lantheus Holdings (NASDAQ:LNTH) Can Manage Its Debt With Ease
Sep 28
PYLARIFY's Strategic Moves Foster Growth In Oncology And Alzheimer's Markets
Aug 28 Expansion into the Alzheimer's diagnostic space and strategic acquisitions suggest diversification and potential for long-term growth in revenue sources.Lantheus: A Radiopharmaceutical Powerhouse In The Making (Q2 2024 Update)
Aug 12Here's Why Lantheus Holdings (NASDAQ:LNTH) Has Caught The Eye Of Investors
Aug 05Investors Appear Satisfied With Lantheus Holdings, Inc.'s (NASDAQ:LNTH) Prospects As Shares Rocket 49%
Jul 17Lantheus Holdings (NASDAQ:LNTH) Is Investing Its Capital With Increasing Efficiency
Jul 16Lantheus Holdings (NASDAQ:LNTH) Could Easily Take On More Debt
Jun 24Leading The Growth Of Radiopharmaceuticals: Mini Deep Dive On Lantheus
May 23Lantheus Holdings, Inc.'s (NASDAQ:LNTH) P/S Is Still On The Mark Following 26% Share Price Bounce
May 10Lantheus Holdings: Powerful First Quarter
May 05Lantheus Holdings: Undervalued With A Good Outlook
Feb 28CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2024 | US$13m | US$855k | US$312m |
| Sep 30 2024 | n/a | n/a | US$428m |
| Jun 30 2024 | n/a | n/a | US$428m |
| Mar 31 2024 | n/a | n/a | US$461m |
| Dec 31 2023 | US$539k | n/a | US$327m |
| Sep 30 2023 | n/a | n/a | US$104m |
| Jun 30 2023 | n/a | n/a | US$33m |
| Mar 31 2023 | n/a | n/a | -US$18m |
| Dec 31 2022 | US$417k | n/a | US$28m |
| Sep 30 2022 | n/a | n/a | US$107m |
| Jun 30 2022 | n/a | n/a | US$32m |
| Mar 31 2022 | n/a | n/a | -US$37m |
| Dec 31 2021 | US$302k | n/a | -US$71m |
| Sep 30 2021 | n/a | n/a | -US$34m |
| Jun 30 2021 | n/a | n/a | -US$27m |
| Mar 31 2021 | n/a | n/a | -US$8m |
| Dec 31 2020 | US$233k | n/a | -US$13m |
| Sep 30 2020 | n/a | n/a | US$389k |
| Jun 30 2020 | n/a | n/a | US$12m |
| Mar 31 2020 | n/a | n/a | US$25m |
| Dec 31 2019 | US$245k | n/a | US$32m |
| Sep 30 2019 | n/a | n/a | US$35m |
| Jun 30 2019 | n/a | n/a | US$39m |
| Mar 31 2019 | n/a | n/a | US$42m |
| Dec 31 2018 | US$242k | n/a | US$41m |
Compensation vs Market: Brian's total compensation ($USD13.44M) is above average for companies of similar size in the US market ($USD8.67M).
Compensation vs Earnings: Brian's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
CEO
Brian Markison (65 yo)
1.1yrs
Tenure
US$13,443,447
Compensation
Mr. Brian A. Markison has served as Chairman of the Board and Chief Executive Officer of Osmotica Pharmaceutical Corp. since 2016. Mr. Markison had been an Operating Executive and Healthcare Industry Execu...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 1.1yrs | US$13.44m | 0.076% $ 5.3m | |
| President | 2.1yrs | US$5.31m | 0.17% $ 12.2m | |
| CFO & Treasurer | 6.6yrs | US$5.43m | 0.17% $ 11.7m | |
| Chief Science Officer | less than a year | US$3.49m | 0.0052% $ 366.0k | |
| Chief Administrative Officer | 4.3yrs | US$4.35m | 0.14% $ 10.2m | |
| Chief Commercial Officer | 2.4yrs | US$2.81m | 0.036% $ 2.5m | |
| Chief Accounting Officer | less than a year | no data | no data | |
| Senior Vice President of Manufacturing & Technical Operations | 2.8yrs | no data | no data | |
| Chief Information Officer | 1.3yrs | no data | no data | |
| Vice President of Investor Relations | no data | no data | no data | |
| VP of Corporate Communications & Chief of Staff | 4.7yrs | no data | no data | |
| Chief People Officer | less than a year | no data | no data |
2.1yrs
Average Tenure
47yo
Average Age
Experienced Management: LNTH's management team is considered experienced (2.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 12.6yrs | US$13.44m | 0.076% $ 5.3m | |
| Independent Director | 12.9yrs | US$494.66k | 0.084% $ 6.0m | |
| Independent Director | less than a year | US$284.68k | 0% $ 0 | |
| Independent Director | 7.2yrs | US$490.91k | 0.045% $ 3.1m | |
| Chairman of the Board | 9.7yrs | US$12.58m | 0.83% $ 58.6m | |
| Independent Director | 3.1yrs | US$483.41k | 0.0069% $ 485.9k | |
| Independent Director | 4.8yrs | US$475.91k | 0.027% $ 1.9m | |
| Lead Independent Director | 8.3yrs | US$483.41k | 0.038% $ 2.7m | |
| Independent Director | 7.2yrs | US$494.66k | 0.030% $ 2.1m | |
| Independent Director | 4.8yrs | US$482.16k | 0.030% $ 2.1m | |
| Independent Director | less than a year | no data | no data |
7.2yrs
Average Tenure
64yo
Average Age
Experienced Board: LNTH's board of directors are considered experienced (7.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/16 10:53 |
| End of Day Share Price | 2025/04/16 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Lantheus Holdings, Inc. is covered by 24 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jeffrey Johnson | Baird |
| Yuan Zhi | B. Riley Securities, Inc. |
| Brian Kemp Dolliver | Brookline Capital Markets |